Table 2 Sociodemographic characteristics of the participants in alpha-testing

Patients

Round 1 (n = 9)

Round 3 (n = 18)

Age (mean, SD)

55.1 (12.4)

63.8 (11.3)

Sex, male

5 (55.6%)

14 (77.8%)

Educational level

 High

 Middle

 Low

5 (55.6%)

4 (44.4%)

-

6 (33.3%)

10 (55.6%)

2 (11.1%)

TKI treatment

 Imatinib

 Dasatinib

 Bosutinib

 Nilotinib

3 (33.3%)

4 (44.4%)

-

2 (22.2%)

9 (50%)*

4 (22.2%)

1 (5.6%)

3 (16.7%)

Patients receiving a lower dose

1 (11.1%)

15 (83.3%)

Type of hospital undergoing treatment

 Academic medical center

 Top clinical

 General hospital

2 (22.2%)

7 (77.8%)

-

5 (27.8%)

11 (61.1%)

2 (11.1%)

Healthcare providers

Round 2 (n = 7)

Round 3 (n = 9)

Sex, female

100%

N/A

Profession

 Hematologist

 Physician-specialist (internal medicine) in training

 Hematology nurse practitioner

7 (100%)

-

-

5 (55.6%)

2 (22.2%)

2 (22.2%)

Hospital

 Academic medical center

 General hospital

4 (57.1%)

3 (42.9%)

1 (11.1%)

8 (88.9%)

Years of experience

 0–5

 > 5

N/A

4 (44.4%)

5 (55.6%)